On November 27, 2025, Cytiva (a subsidiary of Danaher Corporation) and Shanghai Tongjin Stem Cell Technology Co., Ltd. entered into a strategic cooperation memorandum. The duo will collaborate to optimize purification methods for stem cell-derived exosomes, delve into automated production and commercialization of stem cells and exosomes, and bolster the growth of China's biopharmaceutical sector. Liu Zhongmin, Honorary President of the Eastern Hospital of Tongji University, remarked that this partnership signifies a pivotal moment in Tongjin Stem Cell's quest for technological advancement. Luo Fang, Managing Director of Cytiva China's Gene Medicine Operations, voiced eagerness to expedite the commercialization of innovative breakthroughs in China. At present, the industrialization of exosomes encounters hurdles, and this alliance will leverage the combined expertise of both entities, with a focus on achieving breakthroughs in efficient exosome separation and purification techniques, as well as establishing standardized production frameworks. Prior to this, the two entities had already joined forces to set up a collaborative research institute. This latest agreement will propel their partnership from the research and development phase to full-scale industrial deployment, infusing China's pharmaceutical industry with fresh innovative impetus. Moreover, the article provides a concise overview of Tongjin Stem Cell, Cytiva, and Danaher.